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INTRODUCTION
The levonorgestrel-releasing intrauterine system 
(LNG-IUS) has been used since the early 1990s and 
is considered one of the most effective methods of 
contraception1. LNG-IUS is also widely used for other 
clinical purposes, such as reducing heavy menstrual 
blood loss, symptoms of endometriosis, endometri-
al hyperplasia, and endometrial protection during 
post-menopausal estrogen replacement therapy2-5.  
SUMMARY
OBJECTIVE: To evaluate endocervical and vaginal environment changes in women using a levonorgestrel-releasing intrauterine system 
(LNG-IUS). 
METHODS: A quasi-experimental study included sixty women who had an LNG-IUS inserted in the Family Planning Clinic of UNICAMP 
between April and November of 2016. Women in reproductive age, non-pregnant, without the use of antibiotics and contraceptives 
seeking for LNG-IUS insertion were selected for this study. All women were evaluated with regard to vaginal and endocervical pH, vag-
inal and endocervical Gram-stained bacterioscopy, and Pap-smear before and two months after LNG-IUS insertion. Clinical aspects 
such as cervical mucus, vaginal discharge, and cervical ectopy were also observed. 
RESULTS: After LNG-IUS insertion, there was an increase in the following parameters: endocervical pH>4.5 (p=0.02), endocervical neu-
trophil amount (p<0.0001), vaginal cytolysis (p=0.04). There was a decrease in vaginal discharge (p=0.01). No statistically significant 
changes were found in vaginal pH, neutrophils amount in the vaginal mucosa, vaginal discharge appearance, vaginal candidiasis, 
bacterial vaginosis, vaginal coccobacillary microbiota, cervical mucus appearance, or cervical ectopy size. 
CONCLUSIONS: Short-term LNG-IUS use did not increase vulvovaginal candidiasis or bacterial vaginosis, and led to diminished vaginal 
discharge. Notwithstanding, this device promoted reactional changes in the vaginal and endocervical environment, without modifica-
tion on cervical ectopy size. 
KEYWORDS: Levonorgestrel/adverse effects. Contraceptive Agents/adverse effects. Vaginosis, bacterial. Vaginal discharge. 
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METHODS
This quasi-experimental study involving 60 wom-
en was conducted at the Family Planning Clinic of 
CAISM-UNICAMP, Campinas, Brasil, between May 
2016 and December 2016. The study was approved 
by the Research Ethics Committee at the University 
of Campinas, CAAE nº 46001315.7.0000.5404, re-
search project nº 1.208.156, and written informed 
consent was obtained from all participants. Inclu-
sion criteria were: women of reproductive age (be-
tween 18 and 45 years), with regular menstrual 
cycles, sexually active and willing to use long-term 
contraception. As exclusion criteria, we consid-
ered: use of vaginal or systemic antibiotics, or vag-
inal douching in the 30 previous days, current hor-
monal therapy, vulvovaginitis or genitourinary pain 
symptoms, pregnancy, sexual intercourse less than 
6 hours prior to sample collection, uterine anoma-
lies, unexplained bleeding, contraindication to hor-
monal treatment and history of breast cancer. 
The insertion of the LNG-IUS was performed in 
the first phase of the menstrual cycle, shortly after 
the end of menstruation (6th to 9th day), without any 
indication of menstrual bleeding. The insertion pro-
cedure was guided by a pelvic examination, which 
consisted in holding the cervix by a tenaculum and 
passing the uterine sound in order to measure the 
depth of the uterus; next, the IUS was inserted, leav-
ing out approximately 3 centimeters of the string, 
and the women were kept at rest. Analgesics, anes-
thetics, or anti-inflammatory drugs (NSAIDs) were 
not necessary before the insertion. Previously, all 
women were submitted to gynecological examina-
tion, and samples were collected from the vaginal 
wall and endocervix by sterile swabs. The collected 
samples were submitted to bacterioscopy (Gram-
stain) and cytological analysis by Pap smear to 
characterize the type of vaginal flora, inflammatory 
process, presence or absence of pathogens, vaginal 
epithelium lysis, and bacterial vaginosis. Evaluations 
of vaginal and endocervical pH, cervical ectopy, the 
appearance of cervical mucus, and appearance and 
amount of vaginal discharge were also performed. 
To characterize the vaginal pH, a 4.5 cut-off was as-
sumed, considering that normal vaginal range varies 
from 3.8 to 4.511. 
In order to quantify the leukocytes both in the en-
docervix and in the ectocervix, we used Gram-stained 
smears observed at 1000x magnification, scoring the 
slides as follows: 1) absent or discrete frequency: less 
Several studies suggest that the progestogenic 
effects of LNG-IUS and the route of hormone deliv-
ery influence the vaginal microenvironment since 
the cervicovaginal epithelium is directly modulated 
by the action of hormones6-9. Estrogen induces the 
maturation of the cervicovaginal epithelium and 
promotes the accumulation of glycogen in the epi-
thelial cell. Thus, women under a progestin-based 
contraception method have increased parabasal cells 
and decreased intermediate and superficial cells. 
This has a direct impact on the bacterial population, 
since glycogen is an important factor in Lactobacillus 
growth, protecting against genital infections via the 
production of bacteriocins, lactic acid, and mainte-
nance of low vaginal pH10,11.
Data on the impact of LNG-IUS on the cervicovag-
inal epithelium and women’s susceptibility to genital 
infections are controversial. Some investigators have 
shown a general risk to develop a genital infection 
after LNG-IUS insertion12,13. 
A study using 16SrRNA gene technology to char-
acterize the bacterial profiles of vaginal microflo-
ra in women using LNG-IUS showed that bacteria 
typically associated with the dysbiotic vaginal en-
vironment were significantly more abundant than 
in controls6. However, other studies have failed to 
demonstrate an association between such contra-
ceptive method and genital infections or changes in 
the vaginal microbiota7-9. 
Another factor that protects the cervicovaginal 
epithelium is the secreted cervical mucus, which is 
subject to hormone-induced physical or biochemi-
cal alterations, thus affecting the risk of genital in-
fections14. Moreover, the study group has shown 
that changes in the profile of inflammatory cells in 
the vaginal cavity are an important marker of infec-
tions, justifying the investigation of such parameter 
in LNG-IUS users15.  
Cellular alterations in the Pap smear, vagi-
nal bleeding, altered vaginal pH, inflammato-
ry cellular infiltrate in the vagina and cervici-
tis are common adverse effects that need to be 
better investigated in LNG-IUS. This study aims 
to evaluate, in the short term, biochemical, mi-
crobiological, and clinical modif ications in the 
endocervix and vagina after LNG-IUS insertion. 
We hypothesized that the LNG-IUS insertion can 
diminish vaginal discharge due to the progesta-
genic effects on the vaginal epithelium and en-
docervical glands 
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than 4 leukocytes per field; 2) moderate frequency: 
five to nine neutrophils per field; and 3) accentuated 
frequency: more than 10 leukocytes per field. This 
same scoring system was used for the quantification 
of squamous cells in the Pap smear, but at 400x mag-
nification. Regarding cytolysis, we used as a criteri-
on the quantification of the number of nude nuclei of 
intermediate cells in the Pap smear, also using the 
same scoring system described above.
The cervical ectopy diameter was measured and 
was considered discrete when it occupied less than 
half the diameter of the cervix and as moderate or 
accentuated when it occupied more than half the di-
ameter of the uterine cervix.
All patients were evaluated again two months af-
ter the device insertion (± 3 days variation) to avoid 
menstrual cycle variation. Vaginal microbiological 
analysis and characterization of bacterial vaginosis 
were performed based on the Gram-staining method 
and according to the Nugent score16. The existence of 
vulvovaginal candidiasis was indicated by the pres-
ence of yeasts and hyphae, white and lumpy vagi-
nal discharge and inflammation in the vaginal wall. 
Normal flora (Grade I) was defined by the absence of 
pathogens in the analysis of the vaginal smear and 
presence of 80% or more of lactobacilli17. Grade III 
flora was defined when Lactobacilli was substituted 
by coccobacilli or cocci flora (Gram-negative and/or 
anaerobic flora). Grade II was considered an interme-
diate flora.
The evaluation of cellular cytolysis, cellular in-
flammatory alterations, genital infections, and vagi-
nal microbiota was performed both in the Gram and 
Pap samples of the cervix and vagina, relating these 
factors to the vaginal and endocervical pH before and 
after LNG-IUS insertion.
The mean of the intermediate cells in the vagi-
nal mucosa was used to calculate the sample size 
(lowest expected variation and more conservative 
or representative for this study). A 10% beta error, 
a significance level of 5%, and a supposed estimated 
incidence of 40% of intermediate cells were consid-
ered in the patients submitted to the insertion of the 
LNG-IUS. A total sample was estimated in 58 cases. 
The 9.2 version SAS System for Windows (Statisti-
cal Analysis System), SAS Institute Inc, 2002-2008, 
Cary, NC, USA, was used for the statistical analysis. 
The LNG-IUS used was manufactured by Bayer Oy 
(PO Box 415, Fl-20101 Turku, Finland) and the inser-
tion followed the label recommendations. 
RESULTS 
The mean age of the study participants was 32 ± 
7 years (only one patient over 45 years old, aged 52), 
data not shown, of which 44 (73%) were white wom-
en; further socio-demographic information from 
study participants are shown in Table 1.
Clinical, cellular, and microbiological effects 
on the cervix and vagina before and two months 
after insertion of the LNG-IUS are shown in Ta-
ble 2. The number of cases with endocervical pH 
≥ 4.5 increased significantly after insertion (p < 
0.05) and the number of cases with vaginal pH ≥ 
4.5 also increased after insertion of the device, 
although with no statistical significance (73% vs. 
60%, p = 0.116). The presence of neutrophil cells 
was not altered in the vagina (p = 0.317); however, 
it showed a significant increase in the endocervix 
in the presence of LNG-IUS (p < 0.0001). Vaginal 
discharge reported by patients changed from mod-
erate/accentuated to absent/discrete after LNG-
IUS insertion, with a marked decrease in intensity 
(p = 0.011). There were no changes in the appear-
TABLE 1: SOCIO-DEMOGRAPHIC CHARACTERISTICS OF 







Primary school 5 8




1 to 2 40 66
≥ 3 8 13
Parity
0 12 20
1 to 2 43 71
≥ 3 5 8
Number of miscarriages
0 55 91
1 to 2 5 8
≥ 3 0 0
* Including parity and miscarriage
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TABLE 2: CLINICAL, CELLULAR, AND MICROBIOLOGICAL 
ASPECTS RELATED TO THE CERVIX AND VAGINA 






  P value* 
N (% ) N (% )
Endocervical pH 0.0253
≥ 4.5 53 (88) 58 (97)
< 4.5 07 (12) 02 (2)
Vaginal pH 0.1167
≥ 4.5 36 (60) 44 (73)
< 4.5 24 (40) 16 (27)
Neutrophils in endocervix < 0.0001
Moderate/accentuated** 22 (37) 44 (73)
Absent/discrete 38 (63) 16 (27)
Appearance of endocervical mucus 0.1573
Cloudy 1 (2) 3 (5)
Limpid 59 (98) 57 (95)
Neutrophils in vagina 0.3173
Moderate/accentuated 1 (2) 3 (5)
Absent/discrete 59 (98) 57 (95)
Intensity of  vaginal discharge 0.0116
Moderate/accentuated 20 (33) 9 (15)
Absent/discrete 40 (67) 51 (85)
Aspect of vaginal discharge 0.1797
Cloudy 1 (2) 4 (7)
Clear-appearing 59 (98) 56 (93)
Endocervical ectopy 0.2568
Moderate/accentuated 6 (10) 3 (5)
Absent/discrete 54 (90) 57 (95)
Squamous cells predominance*** 0.7389
Intermediate/parabasal 47 (78) 48 (63)
Superficial 11 (18) 7 (12)
Cytolysis 0.0455
Moderate/accentuated 7 (12) 15 (25)
Absent/discrete 53 (88) 45 (75)
Bacterial vaginosis 0.2059
Positive 6 (10) 10 (17)
Negative 54 (90) 50 (83)
Vulvovaginal Candidiasis 1.0000
Positive 3 (5) 3 (5)
Negative 57 (95) 57 (95)
Microflora grading 0.5433
I 48 (80) 45 (75)
II 6 (10) 5 (8)
III 6 (10) 10 (17)
*McNemar or Symmetry test. OR= Odds ratio. CI 95%: Odds ratio 95% confidence 
interval. ** Moderate/accentuated: presence of more than 10 neutrophils in high mag-
nification field (1000 x). *** The lower n value in this analysis is due to a lower number 
of Pap-smears available for analysis of cell dominance (two missing cases before and 
five missing cases after LNG-IUS insertion).
ance of vaginal discharge or cervical mucus (p = 
0.150), and the clear-looking mucus was predom-
inant in both study phases. The predominance of 
TABLE 3: COMPARISON OF ENDOCERVICAL AND 
VAGINAL PH, AND NUGENT SCORE BEFORE AND TWO 
MONTHS AFTER LNG-IUS INSERTION.













Nugent score 2.14  ±  
0.28





6.44  ±  
0.13
6.71  ±  
0.81
0.083 6.17-6.71 6.55-6.87
Vaginal pH 4.69  ±  
0.62





parabasal/intermediate vaginal squamous cells in-
creased from 47 (81%) to 51 (85%), while the super-
ficial cells decreased from 11 (19%) to 7 (15%), with-
out statistical significance (p = 0.738). There was 
a slight increase in vaginal cytolysis (12% vs. 25%, 
p = 0.045) and bacterial vaginosis (10% vs. 17%, p = 
0.205) at the end of the two-month period. 
Table 3 shows that the mean Nugent score was 
slightly higher post-insertion (2.14 ± 0.28 vs. 2.58 ± 
0.35; p = 0.496). The mean value of the endocervical 
and vaginal pH after insertion was not statistically 
different from the pre-insertion period (Table 3).  
Moreover, a case-by-case analysis showed 
that 20 (33%) of the women had some degree of 
increase in Nugent score values after LNG-IUS in-
sertion. The ectopy of the transformation zone in-
creased in size in 3 (5%) of the women, decreased 
in 9 (15%), and remained unchanged in 48  (80%). 
Infection by Candida sp. was diagnosed in three 
women before insertion of the LNG-IUS; in one of 
them, the infection was maintained after insertion 
of the LNG-IUS, but without clinical symptoms. 
Two new cases of Candida sp. were detected after 
insertion of the LNG-IUS.
DISCUSSION
In this paper, we have shown that there was no in-
crease of vaginal candidiasis or bacterial vaginosis, as 
well as no significant changes on cervical ectopy size 
or vaginal discharge after two months of the LNG-
IUS insertion. Although cervical and vaginal pH had 
slight increases and a significant amount of inflam-
matory cells was observed, such factors do not seem 
to be relevant as causes of disease or complaints. 
Taking into consideration that long-term use and/
or microbiological findings after IUS insertion can be 
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confounded with many different risk factors (sexual 
activity, smoking, diet, medication intake, etc), we 
decided to check cervical and vaginal changes after 
only two months, in order to avoid bias. Indeed, the 
increase or decrease of vaginal candidiasis or bacte-
rial vaginosis after one or two years of IUS insertion 
could be related to the patient’s behavior rather than 
only IUS. The majority of published papers in this 
area are frequently focusing only on specific aspects, 
thus neglecting the overview of the cervical and vag-
inal environment as a whole. Certainly, the clinical 
correlation to microscopic findings presented here-
in is a different approach that provides excellent 
strength to our results.  
The insertion of the LNG-IUS seems to promote 
changes in the vaginal and endocervical environ-
ment, without, however, presenting a relevant clini-
cal adverse outcome. The presence of a foreign body 
in any biological cavity is a concern for clinicians, 
whether in the short or long term. In the case of 
intrauterine devices, this concern arises due to the 
possibility of complications such as missing strings, 
ascending infections, uterine perforation, and pelvic 
inflammatory diseases18-20. 
The use of IUDs has increased among young and 
sexually active women in recent years (particularly 
in nulliparous women, although not as much as the 
increase observed for women in general). In 2002, 
only around 0.5% of nulliparous women using con-
traception methods were using an IUD in the United 
States. This rate increased to 4.8% between 2011 and 
201321. In Brasil, the percentage of sexually active 
women using IUDs for contraception is around 3.0%. 
However, this number is also expected to rise in the 
next years despite problems, such as high cost and 
limited availability of the IUDs in the public health 
system that prevent a larger increase22.
The numbers for younger and nulliparous women 
are still smaller than for multiparous women due to 
outdated beliefs and misconceptions about the safety 
of IUD use. Particular concerns such as the risk of 
pelvic inflammatory disease (PID), infertility, safety, 
and difficulty of insertion may still present as biases 
in the provision of this group of women. However, 
recent studies have shown that intrauterine devic-
es are safe and effective for the majority of women, 
including those who are young and nulliparous and 
should be routinely included in the contraception op-
tions offered to them21.
This study evaluated 60 women before and two 
months (in the same phase of the menstrual cycle) 
after the insertion of the LNG-IUS, which induced 
favorable modifications including a decrease of vag-
inal discharge and endocervical ectopy (p=0.256). On 
the other hand, we observed increased cytolysis and 
number of endocervical neutrophils, and endocervi-
cal pH (> 4.5). There were non-significant differences 
in bacterial vaginosis and vaginal candidiasis. This is 
consistent with the overall good acceptance of this 
contraceptive method in clinical practice. 
Our results are in accordance with other re-
searchers who also reported the absence of signifi-
cant changes in the composition of vaginal microflo-
ra or in the frequency of bacterial vaginosis in LNG 
users, even after a long period of time7,9,23,24. Donders 
et al.23 suggest that both hormonal and non-hormon-
al contraceptive methods have a greater tendency 
to present candidiasis, while our study showed a 
non-significant decrease in Candida sp infection after 
a short-term LNG-IUS insertion. 
A decrease in cervical ectopy, as well as, a reduc-
tion in vaginal discharge, could be related to the local 
progestogenic effect of the LNG-IUS. It has been sug-
gested that the possible mechanism responsible for 
the progestogenic and anti-estrogenic effect of LNG-
IUS is the inhibition of the Insulin-like growth factor 
(IGF), which stimulates the proliferation and differ-
entiation of cells that contain IGF membrane recep-
tors, such as epithelial cells25. Hence, the decrease 
in endocervical ectopy found in our study could be 
related to this proliferative mechanism.
Furthermore, the higher frequency of cytolysis af-
ter LNG-IUS insertion found herein can be explained 
by the anti-estrogenic effects of LNG-IUS, leading to 
the predominance of intermediate cells rather than 
superficial cells. The intermediate cells are rich in 
glycogen and, therefore, more susceptible to the cy-
tolysis by lactobacilli, since glycogen is an important 
factor in Lactobacillus growth10,11. 
Our study found an increase in the number of en-
docervical neutrophils after LNG-IUS insertion. This 
was probably a direct physical effect of the LNG-IUS 
string, which can lead to neutrophil chemotaxis and 
can modify the biochemical properties in this envi-
ronment. In fact, it has already been demonstrated 
that LNG-IUS users present an increase in chemok-
ines that promote leukocyte chemotaxis, such as In-
terleukin 8, in the endometrial epithelium26. Another 
study has also demonstrated that users of such IUS 
would be more susceptible to infection by microor-
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RESUMO
OBJETIVO: Avaliar as alterações do ambiente endocervical e vaginal em mulheres usuárias de sistema intrauterino liberador de levo-
norgestrel (SIU-LNG). 
MÉTODOS: Um estudo quase-experimental incluiu 60 mulheres que inseriram o SIU-LNG na Clínica de Planejamento Familiar da 
UNICAMP entre abril e novembro de 2016. Mulheres em idade reprodutiva, não gestantes, sem uso de antibióticos e contraceptivos, 
em busca pela inserção do SIU-LNG, foram selecionadas para este estudo. Todas as mulheres foram avaliadas quanto ao pH vaginal e 
endocervical, bacterioscopia vaginal e endocervical por coloração de Gram, exame de Papanicolau antes e dois meses após a inserção 
de SIU-LNG. Aspectos clínicos como muco cervical, corrimento vaginal e ectopia cervical também foram observados. 
RESULTADOS: Após a inserção do SIU-LNG houve aumento nos seguintes parâmetros: pH endocervical >4,5 (p=0,02), quantidade de 
neutrófilos endocervicais (p<0,0001), citolise vaginal (p=0,04). Houve diminuição do conteúdo vaginal (p=0,01). Não foram encontra-
das alterações estatisticamente significativas no pH vaginal, na quantidade de neutrófilos na mucosa vaginal, apecto do corrimento 
vaginal, candidíase vaginal, vaginose bacteriana, microbiota cocobacilar vaginal, aparência de muco cervical ou tamanho da ectopia 
cervical. 
CONCLUSÃO: O uso do SIU-LNG em curto prazo não aumentou a candidíase vulvovaginal ou a vaginose bacteriana, levou à diminuição 
do conteúdo vaginal. No entanto, este dispositivo promoveu mudanças reacionais no ambiente vaginal e endocervical, sem modifi-
cação no tamanho da ectopia cervical.
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